SCHEMBL2740998

SCHEMBL2740998

NNc1ccc([N+](=O)[O-])cc1S(=O)(=O)Nc1ccccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHBP P24387 1/20 0.60
▸ CRHR2 Q13324 1/20 0.60
▸ NHERF1 O14745 1/20 0.51
▸ GUSB P08236 1/20 0.49
▸ MCL1 Q07820 2/20 0.48
▸ MEN1 O00255 7/20 0.46
▸ KMT2A Q03164 7/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.46
▸ HTT P42858 4/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ PSMD14 O00487 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ NFKBIA P25963 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ MAPT P10636 6/20 0.43
▸ LMNA P02545 3/20 0.43
▸ SLC5A1 P13866 1/20 0.43
▸ NCOA1 Q15788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15647549 0.84 NFKBIA (0.61) CRHBPCRHR2NHERF1GUSBMCL1
SCHEMBL2741009 0.83 CA2 (0.58) CRHBPCRHR2GUSBMCL1MEN1
SCHEMBL2740946 0.82 CRHBP (0.59) CRHBPCRHR2NHERF1GUSBMCL1
SCHEMBL2741012 0.82 CRHBP (0.53) CRHBPCRHR2NHERF1GUSBMCL1
SCHEMBL14161620 0.80 POLB (0.60) GUSBMCL1MEN1KMT2ASMN1; SMN2
SCHEMBL2740966 0.80 CRHBP (0.57) CRHBPCRHR2NHERF1GUSBMCL1
SCHEMBL2740989 0.79 MEN1 (0.52) CRHBPCRHR2NHERF1GUSBMCL1
SCHEMBL2741006 0.78 MEN1 (0.55) CRHBPCRHR2NHERF1MCL1MEN1
SCHEMBL1970882 0.78 CRHBP (0.72) CRHBPCRHR2MEN1KMT2ASMN1; SMN2
SCHEMBL2740971 0.78 CRHBP (0.49) CRHBPCRHR2NHERF1GUSBMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
WO-2008071398-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2008-06-19 — — WO disclosed
EP-1932830-A1 Sulfonamides and their use as a medicament The Genetics Company, Inc. (CH) 2008-06-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 CRHBP 2638/4885CRHR2 524/4885NHERF1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback